|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity显示文摘Background:Obesity is often associated with nonalcoholic fatty liver disease(NAFLD),which refers to a large spectrum of hepatic lesions including fatty liver,nonalcoholic steatohepatitis(NASH)and cirrhosis.Different investigations showed or suggested that obesity and NAFLD are able to increase the risk of hepatotoxicity of different drugs.Some of these drugs could induce more frequently an acute hepatitis in obese individuals whereas others could worsen pre-existing NAFLD.Aim:The main objective of the present review was to collect the available information regarding the role of NAFLD as risk factor for drug-induced hepatotoxicity.For this purpose,we performed a data-mining analysis using different queries including drug-induced liver injury(or DILI),drug-induced hepatotoxicity,fatty liver,nonalcoholic fatty liver disease(or NAFLD),steatosis and obesity.The main data from the collected articles are reported in this review and when available,some pathophysiological hypotheses are put forward.Relevance for patients:Drugs that could pose a potential risk in obese patients include compounds belonging to different pharmacological classes such as acetaminophen,halothane,methotrexate,rosiglitazone,stavudine and tamoxifen.For some of these drugs,experimental investigations in obese rodents confirmed the clinical observations and unveiled different pathophysiological mechanisms which could explain why these pharmaceuticals are particularly hepatotoxic in obesity and NAFLD.Other drugs such as pentoxifylline,phenobarbital and omeprazole might also pose a risk but more investigations are required to determine whether this risk is significant or not.Because obese people often take several drugs for the treatment of different obesity-related diseases such as type 2 diabetes,hyperlipidemia and coronary heart disease,it is urgent to identify the main pharmaceuticals that can cause acute hepatitis on a fatty liver background or induce NAFLD worsening. | Julie Massart Karima Begriche Caroline Moreau Bernard Fromenty | 2017 | Journal of Clinical & Translational Research2017，3，1： | 4 |
| 2 | Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role显示文摘 | J. Aubert K. Begriche L. Knockaert M.A. Robin B. Fromenty | 2011 | Clinics and Research in Hepatology and Gastroenterology2011，，10： | 3 |
| 3 | Differences in early acetaminophen hepatotoxicity between obese ob/ob and db/db mice显示文摘 | Aubert J Begriche K Delannoy M | 2012 | J Pharmacol Exp Ther2012，342，3： | 1 |
| 4 | Mitoehondrial dysfunction in NASH: causes, consequences and possible to prevent it显示文摘 | Begriche K Igoudjil A Pessayre D | 2006 | Mitochondrion2006，6，1： | 1 |
| 5 | Mitochondrial dysfunction in NASH:Causes,consequences and possible means to prevent it显示文摘 | Begriche K Igoudjil A Pessayre D | 2006 | Mitochondrion2006，6，1： | 1 |
| 6 | Beta- Aminoisobutyric acid preventsdiet-induced obesity in mice with partialleptin deficiency显示文摘 | Begriche K Massart J Abbey-Toby A | 2008 | Obesity (Silver Spring)2008，16，9： | 1 |
| 7 | Mitochondrial dysfunction in nonalcoholic steatohepatitis(NASH):are there drugs able to improve it显示文摘 | Begriche K KnockaertL Massart J | 2009 | Drug Discov Today2009，6，14： | 1 |
| 8 | Effects of 13-aminoisobutyric acid on leptin production and lipid homeostasis: mechanisms and possible relevance for the prevention of obesity显示文摘 | Begriche K Massart J Fromenty B | 2010 | Fundam Clin Pharmacol2010，24，3： | 1 |
| 9 | Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it显示文摘 | BEGRICHE K IGOUDJIL A PESSA YRE D | 2006 | Mitochondrion2006，，： | 1 |
| 10 | Mitochondrial dysfunction in NASH:causes,consequences and possible means to prevent it显示文摘 | Begriche K Igoudjil A Pessayre D | 2006 | Mitochondrion2006，6，： | 1 |
| 11 | Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle显示文摘 | Sutton GM Begriche K Kumar KG | 2010 | FASEB J2010，24，3： | 1 |
| 12 | Drug-induced toxicity on mitochondria and lipid metabolism:mechanistic diversity and deleterious consequences for the liver显示文摘 | Begriche K Massart J Robin MA Borgne-Sanchez A Fromenty B | 2011 | J Hepatol2011，54，4： | 1 |
| 13 | Increased expression of cytochrome P450 2El in nonalcoholic fatty liver disease: mecha- nisms and pathophysiological role 显示文摘 | Aubert J Begriche K Knockaert L | 2011 | Clin Res Hepatol Gastroen- terol2011，35，： | 1 |
| 14 | Mitochondrial dysfunc- tion in NASH: causes, consequences and possible means to prevent it 显示文摘 | Begriche K Igoudjil A Pessayre D | 2006 | Mitochondrion2006，6，1： | 1 |
| 15 | Mitochondrial dysfunction in NASH :Causes, consequences and possible means to prevent it显示文摘 | Begriche K Igoudjil A Pessayre D | 2006 | Mitochondrion2006，6，1： | 1 |
| 16 | Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious eonsequences for the liver 显示文摘 | Begriche K Massart J Robin MA | 2011 | J Hepatol2011，54，4： | 1 |
| 17 | Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it显示文摘 | Begriche K Igoudjil A Pessayre D | 2006 | Mitochondrion2006，6，1： | 1 |
| 18 | Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it 显示文摘 | Begriche K Igoudjil A Pessayre D | 2006 | Mitochondrion2006，6，1： | 1 |
| 19 | Genetic dissection ofthe functions of the melanocortin-3 receptor, a seven-transmembrane G-protein-coupled receptor, suggests roles forcentral and peripheral receptors in energy homeostasis 显示文摘 | Begriche K Levasseur P R Zhang J | 2011 | Journal Biology Chemistry2011，，40： | 1 |
| 20 | Mitochondrial dys- function in NASH : causes, consequences and possible means to prevent it显示文摘 | BEGRICHE K IGOUDJIL A PESSAYRE D | 2006 | Mitochondrion2006，6，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员